病例报告:巴里西提尼布在患有亚托皮性皮肤炎的儿科患者中改善了白发症
Sihan Wang1, Ziqian Xu1, Xiaoxia Zhu1
1Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, China.
Frontiers in pediatrics
|January 27, 2025
概括
这项研究表明,巴里西替尼有效地治疗了患有骨髓质疏松症的儿童的严重脱发症 (AA) 和皮炎 (AD). 治疗导致了显著的头发再生,并减少了湿疹的严重程度,副作用最小.
科学领域:
- 儿科皮肤病学 儿科皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脱发症 (AA) 和皮炎 (AD) 是常见的炎症性疾病,在儿童中经常同时发生.
- AA和AD的致病性是复杂的,并未完全理解,特别是在患有伴随性疾病的儿科病例中,如严重肌痛症.
- 以前的皮质固醇治疗无效,导致AA和AD恶化.
研究的目的:
- 报告一例严重的AA和中度的AD在患有肌痛性骨髓质疏松症的儿科患者身上.
- 评估巴里西提尼布在治疗这种复杂病例中的疗效和安全性.
- 讨论Janus激酶 (JAK) 抑制剂对于儿科AA和AD的潜力.
主要方法:
- 一名患有严重AA,中度AD和肌痛性肌痛症的儿科患者接受了巴里西提尼布 (每天4毫克) 和局部皮质类固醇药膏治疗.
- 治疗结果使用脱发严重程度工具 (SAT) 评分和湿疹区域和严重程度指数 (EASI) 进行评估.
- 镜检查用于评估头发的再生,常规血液检查监测安全参数.
主要成果:
- 观察到显著的改善,SAT分数从100下降到24.4,EASI分数减少到0.
- 三镜检查显示了新的羊毛毛发生长,表明成功的头发再生.
- 患者耐受好巴里西提尼布,血细胞和器官功能正常,除了轻微的头皮毛囊炎.
结论:
- 巴里西提尼布是一种JAK抑制剂,在治疗严重的AA和AD患者中表现出显著的疗效.
- 这一案例凸显了JAK抑制剂作为AA和AD复杂儿科病例的安全有效治疗选择的潜力.
- 对儿童自身免疫疾病的JAK抑制剂进行进一步的研究是有必要的.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Inflammatory Bowel Disease IV: Pharmacological Management
106
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
106
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118


